News & Videos - TEVA PHARMACEUTICAL INDUSTRIES

You are currently viewing all stock exchange news of the financial instrument TEVA PHARMACEUTICAL INDUSTRIES regarding all markets in all languages.

> News GlobeNewsWire published a news.

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals • • GlobeNewsWire • Stocks

SANTA BARBARA, Calif. and PARSIPPANY, N.J. , Feb. 27, 2025 (GLOBE NEWSWIRE) -- Direct Relief, Teva Pharmaceuticals, and the National Association of Free and Charitable Clinics (NAFC) today announced the funding of Community Routes: Access to Mental Health Care grants, awarding $75,000 to each of 11 free and charitable clinics across Alabama, Mississippi, and Texas. Now in its third year, the initiative continues to address the critical need for expanded mental health services in medically...

Thank you Chart

> News GlobeNewsWire published a news.

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder • • GlobeNewsWire • Stocks

UZEDY is currently approved in the US as a subcutaneous long-acting injectable (LAI) for use every one or two months for the treatment of schizophrenia in adults 1 LAI treatment options may help address unmet needs of people living with bipolar I disorder (BP-I) BP-I filing acceptance for UZEDY represents Teva’s commitment to pursuing new advances in neuroscience PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva...

Thank you Chart

> News GlobeNewsWire published a news.

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease • • GlobeNewsWire • Stocks

New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different doses New endpoints presented include findings on clinical and endoscopic outcomes and histological- endoscopic mucosal improvement Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025 PARSIPPANY, N.J. and PARIS, Feb. 22, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd....

Thank you Chart

> News GlobeNewsWire published a news.

Der Patient steht an erster Stelle: Warum Europa handeln muss, um den Zugang zu Arzneimitteln zu sichern • • GlobeNewsWire • Stocks

AMSTERDAM, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Laut einer neuen Studie von Teva Pharmaceuticals Europe werden 46 % der Generika auf der EU-Liste der kritischen Arzneimittel von nur einem Anbieter bereitgestellt. Wenn man Anbieter mit einem Marktanteil von über 60 % betrachtet, verdoppelt sich diese Zahl auf 83 %. Die Studie Generic Health Check Europe 3.0 zeigt, dass die Marktkonsolidierung bei kritischen Generika dreimal schneller voranschreitet als bei anderen Generika. Dies stellt ein...

Thank you Chart

> News GlobeNewsWire published a news.

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S. • • GlobeNewsWire • Stocks

In October 2024, t he U. S. Food and Drug Administration (FDA) approved SELARSDI ™ for all indications matching the reference product Stelara ® ( ustekinumab ) and has granted a provisional determination of interchangeability for SELARSDI SELARSDI is the second biosimilar to launch in the U.S. under the Teva and Alvotech strategic partnership , which includes nine products SELARSDI is approved for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults...

Thank you Chart

> News GlobeNewsWire published a news.

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO) • • GlobeNewsWire • Stocks

TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will conduct a conference call and live webcast at 8 am E.T. on Monday, February 24, 2025. During the conference call, Eric Hughes, MD, PhD, Executive Vice President of Global R&D and Chief Medical Officer, and external IBD key opinion leaders (KOLs) will discuss new data presented for duvakitug (anti-TL1A) positive Phase 2b results at the 20th Annual Congress of...

Thank you Chart

> News GlobeNewsWire published a news.

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) • • GlobeNewsWire • Stocks

REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT06, Alvotech’s proposed biosimilar to...

Thank you Chart

> News GlobeNewsWire published a news.

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth • • GlobeNewsWire • Stocks

2024 Revenues of $16.5 billion reflect an increase of 6%, in local currency terms, compared to 2023; AUSTEDO ® - exceeding $1.6 billion in revenues, surpassing 2024 outlook; AJOVY ® - global annual revenues of $507 million, an increase of 18% in local currency terms compared to 2023; UZEDY ® revenues of $117 million in 2024 surpassing $100M outlook; Generics business continues to grow across all segments, with increases of 15% in the U.S., 6% in Europe and 15% in International Markets, all in...

Thank you Chart

> News GlobeNewsWire published a news.

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab) • • GlobeNewsWire • Stocks

REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Biologics License Applications (BLA) for AVT05, Alvotech’s proposed biosimilar to...

Thank you Chart

> News GlobeNewsWire published a news.

Teva annonce un partenariat en vue de commercialiser le candidat biosimilaire de Formycon à Eylea® (aflibercept) dans la majeure partie de l’Europe et en Israël • • GlobeNewsWire • Stocks

Klinge Biopharma GmbH (Klinge) détient les droits exclusifs de la commercialisation mondiale de FYB203, le candidat biosimilaire de Formycon, à Eylea ®1 L’accord repose sur la collaboration éprouvée et fructueuse de la commercialisation de FYB201, le biosimilaire de Formycon à Lucentis ®2 (ranibizumab) en Europe Le partenariat permet d’élargir le portefeuille de biosimilaires de Teva, conformément à sa stratégie « Pivot to Growth » TEL AVIV, Israël, 14 janv. 2025 (GLOBE...

Thank you Chart

> News GlobeNewsWire published a news.

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel • • GlobeNewsWire • Stocks

Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea ® 1 Agreement builds on the proven and successful collaboration of commercialization of FYB201, Formycon's biosimilar to Lucentis ® 2 (ranibizumab) in Europe The partnership broadens Teva's biosimilars portfolio, in line with its Pivot to Growth strategy TEL AVIV, Israel, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary...

Thank you Chart

> News GlobeNewsWire published a news.

Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States • • GlobeNewsWire • Stocks

Marks a step forward in b roadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH) , atypical hemolytic uremic syndrome ( aHUS ) and generalized myasthenia gravis ( gMG ) in the U . S . P artnership supports Teva's Pivot to Growth strategy and adds to i t s broad biosimilar portfolio INCHEON, Korea and TEL AVIV, Israel, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced today that the...

Thank you Chart

> News GlobeNewsWire published a news.

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference • • GlobeNewsWire • Stocks

TEL AVIV, Israel, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time). To access a live webcast of the presentation, visit Teva’s Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations . An...

Thank you Chart

> News GlobeNewsWire published a news.

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025 • • GlobeNewsWire • Stocks

TEL AVIV, Israel, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2024 financial results, as well as on its financial guidance for 2025, on Wednesday, January 29, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a...

Thank you Chart

> News GlobeNewsWire published a news.

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease • • GlobeNewsWire • Stocks

Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpoint results in UC and CD for high dose represent the highest achieved with any TL1A monoclonal antibody Sanofi and Teva plan to initiate Phase 3 development in IBD, pending regulatory discussions PARSIPPANY, N.J. and PARIS, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE:...

Thank you Chart

> News GlobeNewsWire published a news.

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients • • GlobeNewsWire • Stocks

Teva to provide two generic inhaler products to Direct Relief for its network of free and charitable clinics The program , launc hing this month, will run for a minimum of three years PARSIPPANY, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of a new patient access program, in partnership with Direct Relief, to supply inhalers to eligible patients in the United States...

Thank you Chart

> News GlobeNewsWire published a news.

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan • • GlobeNewsWire • Stocks

Teva entered into an agreement with JKI Co., Ltd. ( “JKI” ) established by the fund managed and operated by private equity firm J-Will Partners Co., Ltd. ("J-Will”), through which JKI will acquire Teva-Takeda The agreement is aligned with Teva's Pivot to Growth strategy to focus its business The expected divestment of Teva-Takeda, Teva's business venture in Japan, which includes generics products and legacy products, will allow Teva to focus on bringing its innovative medicines to the...

Thank you Chart

> News GlobeNewsWire published a news.

Teva présente des données positives sur l’efficacité et la sécurité d’emploi d’AJOVY® (frémanézumab) pour la prévention de la migraine épisodique chez les enfants et les adolescents dans le cadre de l’essai clinique de phase III SPACE • • GlobeNewsWire • Stocks

AJOVY ® (frémanézumab) a permis de réduire de manière significative le nombre de jours de migraine mensuels (MMD, de l’anglais « monthly migraine days ») et le nombre de jours de céphalées mensuels (MHD, de l’anglais « monthly headache days ») par rapport au placebo sur une période d’administration de 12 semaines chez des patients pédiatriques âgés de 6 à 17 ans 1 Efficacité conforme aux études pivots de phase III et aux données recueillies en conditions réelles portant...

Thank you Chart

> News GlobeNewsWire published a news.

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial • • GlobeNewsWire • Stocks

AJOVY ® (fremanezumab) significantly reduced monthly migraine days (MMD) and monthly headache days (MHD) versus placebo over a 12-week period in pediatric patients aged 6-17 years 1 Efficacy consistent with fremanezumab pivotal Phase 3 and Real-World Evidence studies in adults with no new emergent safety signals observed Full data presented as a late breaker at European Headache Congress (EHC) 4-7 December in Rotterdam, Netherlands TEL AVIV, Israel, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Teva...

Thank you Chart

> News GlobeNewsWire published a news.

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference • • GlobeNewsWire • Stocks

TEL AVIV, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and Eric Hughes, Teva’s Executive Vice President of Global R&D and Chief Medical Officer, will present at the 7 th Annual Evercore ISI HealthCONx Conference on Thursday, December 5, 2024. The presentation will begin at 8:20 A.M. Eastern Time. To access a live webcast of the presentation, visit Teva’s Investor Relations...

Thank you Chart